In the setting of established and (rapidly) proliferating disease, there is a need to enhance and sustain T-cell function, activity, and persistence. However, too many inhibitory and not enough costimulatory signals are a major hurdle. But one way to overcome this is with immunomodulatory fusion proteins, such as this https://ashpublications.org/blood/article/130/22/2410/36564/A-CD200R-CD28-fusion-protein-appropriates-an
Adding CD8 coreceptors may enhance CD4+ T-cell responses (for MHC Class I-restricted antigens) by stabilising TCR-pMHC interactions. Also, it serves to enhance avidity from low affinity TCRs, while enhancing activation https://www.tandfonline.com/doi/full/10.4161/onci.22590
Market Data 
Markets 
AI
